AzTrials
AzTrials

Severe Enduring Anorexia NervosaNCT01924598

Pilot Study of Deep Brain Stimulation for Severe Anorexia Nervosa

A study testing DBS to nucleus accumbens/anterior limb of internal capsule in people with Severe Enduring Anorexia Nervosa, run by University of Oxford at 2 sites in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Anorexia Nervosa (AN) has the highest mortality of any psychiatric disorder and a paucity of effective treatments. AN becomes intractable in around 20%, resulting in huge individual and healthcare costs. Exploration of underlying processes and novel treatment strategies is thus crucial. Read more about this study

Who is it for?
Ages 20 to 65 years, women only
Conditions the study is for
Severe Enduring Anorexia Nervosa
What is being tested?
DBS to nucleus accumbens/anterior limb of internal capsule
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
2 sitesUnited Kingdom
Study dates
Jul 2013to Jun 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Primary diagnosis: Anorexia Nervosa according to the DSMIV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition)criteria based on a psychiatric interview
  • Illness duration of severe AN > 7 years
  • Disabling severity with substantial functional impairment
  • Female Gender and right handed
  • Treatment refractoriness, defined as lack of response to two or more typical modes of treatment, such as inpatient weight restoration, psychotherapy and psychopharmacology
  • Severely underweight: BMI >13 <16
Show all 12Show fewer
  • Age: 20-65 years old
  • Written informed consent
  • Able to fully understand the consequences of the procedure
  • English speaking and able to answer the study questions fluently
  • Having the mental capacity to make provide informed consent to research participation
  • -

Who cannot join

  • Unstable physical condition (severe electrolyte disturbances, cardiac failure, other physical conditions due to underweight in which surgery/anaesthesia is contraindicated)
  • Treatable underlying cause of anorexia/underweight
  • Parkinson's disease, dementia, epilepsy
  • History of schizophrenia/ psychosis, bipolar disorder
  • Alcohol or substance abuse (including benzodiazepines) during the last 6 months
  • Current severe major depressive or Tic disorder
Show all 10Show fewer
  • Antisocial or Severe Borderline Personality Disorder
  • Standard MRI scan exclusion criteria (pregnancy, pacemaker and metals contraindicated for MRI except for the DBS implantation and stimulator itself)
  • Current Involuntary patient
  • -

Trial locations and contacts

2 sites in 1 country.

United Kingdom2 sites
  • University of Oxford Dept Psychiatry , Warneford Hospital

    Oxford, Oxfordshire, OX37JX

  • Nuffield Dept Surgery, University of oxford

    Oxford

Other trials in United Kingdom

About this study

Official title: Hungry for Reward : A Pilot Investigation of the Ethics, Practice and Neural Basis of Deep Brain Stimulation to the Nucleus Accumbens in Severe Intractible Anorexia Nervosa.

Anorexia Nervosa (AN) has the highest mortality of any psychiatric disorder and a paucity of effective treatments. AN becomes intractable in around 20%, resulting in huge individual and healthcare costs. Exploration of underlying processes and novel treatment strategies is thus crucial. This is a pilot study of a novel translational approach to the investigation and treatment of severe AN. The aims are (1) to explore the safety, acceptability and feasibility of Deep Brain Stimulation (DBS) for AN (2) to map neural mechanisms underpinning aberrant reward and optimise DBS targets. The study will involve 10 consenting adults with full mental capacity, and the nain protocol will last 15 months. . There is then optional annual follow ups for up to 5 years .It incorporates an ethical substudy including assessment of capacity and informed consent. It combines complementary forms of cutting edge neuroimaging including fMRI and MEG (magnetoencephalography). These will be complimentary in helping identify the best strategy for treating severe AN using DBS. Individuals with severe intractable AN will be eligible to take part. The study will be conducted in Oxford, United Kingdom at the John Radcliffe and Warneford Hospitals. The individuals will have preoperative ethical, neuroimaging and psychological assessments, A DBS operation in month 2, DBS switch on in month 3 month postoperatively . DBS will be targeted to the Nucleus accumbens, followed by a 12 month post switch on follow-up period with monthly joint neurosurgical psychiatric and psychological assessments and postoperative MEG scans . The study will further our understanding of food reward processes in general and AN in particular indeed promises to provide important information which may revolutionize future treatments. The proposal builds upon a body of research investigating the role of aberrant reward processes in AN and exploits our complementary research experience in AN using experimental behavioural strategies, fMRI , MEG and DBS to establish a powerful translational research strategy.

Read the detailed description

Our hypothesis, based on prior research, is that DBS to the nucleus accumbens will have beneficial neural and symptomatic effects in severe Anorexia Nervosa.

As a test of this hypothesis, and to evaluate acceptability and ethical issues we aim to initially study up to 10 patients.

This study may provide important clinical and scientific information to contribute to larger studies.

DESIGN SUMMARY The design will consist of a case series of 10 patients with repeated measures. The individuals will be aged 20-65 with at least 7 years history of severe treatment resistant AN, who are fully consenting and motivated to recover.

The patients will be selected on the basis of specific suitability criteria. A small case series study design is needed as this is a novel and invasive strategy, and further information about acceptability, feasibility and neural processes involved is required to inform more extensive studies. This can optimally be obtained by initial detailed study of a small number of patients. As some heterogeneity of response is likely, as advised by our external reviewer Professor Walter Kaye, we are aiming to study 10 patients ..

The intervention will be bilateral deep brain stimulation targeted at the nucleus accumbens with stimulation at the ventral anterior limb of the internal capsule. Following DBS each patient will be followed up every month weeks for 13 months.

First, after recruitment there will be a 2 month preoperative period of thorough preoperative examination of ethical issues including qualitative and semi structured interviews (MacCATCR (MacArthur Competence Assessment Tool for Clinical Research))to assess competence and informed consent will be completed by an independent researcher experienced in ethical issues in AN (Jacinta Tan).

The study participants will then be have the initial research assessment and will be reviewed every month in joint eating disorders psychiatry -neurosurgery clinics . In month 10 there will be two randomly assigned 2 week periods of active or sham stimulation,.

monthly assessments will include : • BMI • Semi structured interviews : Eating Disorder Eating Disorder Examination (EDE)

  • Yale Brown CornellEating Disorder Scale (YBCEDS)
  • Observer rated comorbidity (SCID / Hamilton Depression rating scale)
  • Computerized behavioural tasks: Food reward (Leeds-Oxford food preference task) habit formation tasks
  • Self report schedules: EDE Questionnaire, functional impairment (CIA) , quality of life scale (WHOQUALBREF); starvation dependence scale, Beck Depression Inventory (BDI, Beck et al. 1961), the State Trait Anxiety Inventory (Spielberger, 1998), the Snaith-Hamilton pleasure scale (SHAPS, Snaith et al. 1995) and the Ruminative Response Scale for Eating Disorders (RRSED). Pre-operative imaging will involve fMRI and MEG. Post-operative imaging will involve 3 MEG scans, two in month 10 and at study end, 15 months.

DETAILS OF METHODOLOGY:

Subjects selection and recruitment:

A list of eligible patients, fulfilling inclusion and exclusion criteria will be made in discussion with Specialist Eating Disorder services clinicians. Patients will be ranked in order of suitability according to specific suitability criteria:

  1. Severity and intractiblity of Anorexia Nervosa ii. Restrictive anorexia nervosa - without binging/purging iii. Absence of currently severe comorbid depression or self-harm iv. Ideally on no, or minimal Psychotropic medication v. No recent history of compulsory treatment ( i.e. in the last year) vi. Has tried existing treatment options without success vii. Has never had periods of full remission viii. Intensity of desire to recover ix. Good intellectual function and education - well able to comprehend the facts of the intervention (e.g. healthcare background, university education) x. Poor social and occupational function, high levels of distress - not functioning well, having poor quality of life.

The highest ranked patients will be asked if they consent to receiving information about the project. If they are interested they will be approached by Dr Park with information about the project, given an information sheet and the opportunity to discuss with family members. If they remain interested they be will be offered the opportunity to meet with Dr Park and Professor Aziz, for further information and to address questions , and involve their family if they wish. Following this they will be reviewed by Dr Park a week later and thus given a up to week to decide if they would like to participate. Consent to participate in the project will be taken by Dr Park and can be freely withdrawn at any point with no effect on their usual clinical care. Throughout the study the patients will receive supportive treatment as usual from the clinical team who will be independent from the research team, and it will be made clear they can opt out of the study at any point without having to give explanations.

If the patient consents to participation they will have preoperative assessments in the University Research Department at the Warneford hospital:

I: PREOPERATIVE PHASE: 2 months

  1. Initial assessment with Research team. BMI: height and weight Semi structured interviews of Eating Disorder and comorbidity: EDE, SCID, Yale-Brown-Obsessive Compulsive scale ( YBOCS); Self reported questionnaires as above indexing mood and quality of life Computerised Behavioural tasks: Leeds -Oxford food preference task , Habit formation task
  2. Weekly self report measures of symptoms done at home, weekly (5 minutes) using the' True Colours' online self monitoring system pioneered at the University of Oxford Department of Psychiatry, adapted for Eating disorders by Dr Park including the OXBREAD brief rating scale. http://oxtext.psych.ox.ac.uk/true-colours. This self report system will continue from entry to the study end. These self report schedules will be augmented by brief weekly on - line face to face reviews by skype or face time with the aim of offering participants maximal support and monitoring.
  3. Neuropsychological assessment battery, duration approximately 1 hour: (Neuropsychological assessments are routine for all DBS operations done in Oxford).
  • WAIS IV subtests : Vocabulary , Matrix Reasoning , Digit Span , Coding (Wechsler 2008): Measures of general intellectual skills that is needed to make sense of performance across other cognitive domains.
  • BIRT Memory and Information Processing Battery : List Learning Task. Baseline measure of Verbal Memory and Learning( Coughlan, Oddly, \& Crawford, , 2007).
  • Verbal Fluency. Baseline measure of Phonemic and Semantic Fluency(Spreen ,\& Strauss 1998).
  • CANTAB: IED and SWM subtests: Assess executive faculties such as set shifting and spatial working memory (Robbins, James, Owen, Sahakian, McInnes\& Rabbitt, 1994)
  1. Preoperative Capacity assessment Once each suitable patient is identified, and consented , Dr Jacinta Tan will interview the patient independently to do a full MacCAT-CR assessment plus in depth interview to explore the patient's experience of treatment, rationale for participation and motivations for taking part in research from the participants' perspective, to ensure a high level of capacity , voluntariness and informed consent. The assessment is expected to take 2.5 -3 hours and can be done in sections if the patient tires. It will be tape recorded and transcribed. Jacinta will score the MacCAT-CR and an independent observer will also score the MacCAT-CR. Both will also provide global assessments of capacity to consent to research. Dr Tan will provide a detailed report of the interview and her assessment of ethical acceptability of participation for that individual. If she decides the patient is not suitable, the process will be repeated with the next individual on the list who agrees.
  2. Neuroimaging:

Pre-operatively the patient will have:

a whole brain MRI scan including T1, T2, Inversion Recovery sequences and fMRI in resting state and task based using our food reward task: These scans will occur at the John Radcliffe Hospital , Oxford; total duration 1 hour.

a whole brain MEG scan- resting state and task based food reward task , which will be done at the Warneford Hospital, Oxford, duration 30 minutes.

Medical optimisation: patients will have normalisation of electrolytes and ECG prior to being considered fit for the operation. They will need to be a BMI of> 13.

II OPERATIVE PHASE: Month 2.

The DBS operation-will require up to 4 days of inpatient stay at the John Radcliffe Hospital On the day of surgery, the patient will be anaesthetised and the base ring fixed to the skull and a CT scan performed with a localiser fixed to the ring. The patient will then be transferred to theatre and the scalp cleansed.

By fusing the structural MRI scan to the stereotactic CT scan the trajectory to implant electrodes into the nucleus accumbens bilaterally will be calculated. Then through bilateral scalp incisions and a twist drill skull perforation, deep brain electrodes will be passed to target bilaterally and fixed to the skull with titanium mini-plates. The scalp will then be closed and a repeat stereotactic CT scan will be obtained to confirm electrode placement.

Having done so, back in theatre the electrodes will be connected to extension cables that will then be passed sub-cutaneously down one side of the head, behind the ear to a sub-cutaneous pouch below the collar bone and connected to a rechargeable pacemaker and all the wounds closed. Video recordings are used as part of the assessment process during routine implantation of DBS wires whether taking part in a study or not and is therefore considered part of standard operating procedure. They will be assessed as part of the study to measure the response to DBS.

The day after surgery, the pacemaker will be turned on to ascertain any immediate effects of stimulation on symptoms and then switched off again. Having done so the patient will be discharged two days after implant to be assessed six weeks after implant when all wounds are healed and any acute effects of the DBS electrode insertion operation such as headaches, scalp soreness or wound tenderness have worn off.

III: POST OPERATIVE FOLL0W-UP PHASE: Month 3 ( off): Month 4-15: DBS On

In the first post -operative month the stimulator will remain off. At the end of Month 3: post op MEG, followed by DBS switch on Month 4-6: 3 month dose optimisation period: dose adjustment may require more frequent visits to Oxford, up to weekly, for neurosurgical review Months 7-9: Dose stabilization period Month 10: Two fortnight periods of double blind either DBS On or off. MEG scans in each condition.

Months 11-15: DBS at stable optimised dose. At month 15: Final MEG scan, neuropsychology

Post operative assessments, aiming to track the neural and symptomatic change as a result of DBS will involve:

  1. Continuation of weekly self report rating scale of eating disorder, anxiety and depression involving the True Colours text messaging system started in phase I: http://oxtext.psych.ox.ac.uk/true-colours (5 minutes)
  2. Monthly reviews (up to 2 hours) in the Warneford Research department incorporating:
  • Interview with Dr Park , research assistant and/or DPhil student: BMI: Semi structured interviews including Eating Disorder Eating Disorders Examination (EDE), comorbid psychopathology (SCID) Yale-Brown-Obsessive Compulsive Scale (YBOCS), . Behavioural paradigms: food reward (Oxford-Leeds food preference task, habit task; Self report schedules as in phase 1 assessing eating disorder symptoms, starvation dependence, functional impairment and quality of life .
  • Joint Neurosurgery-psychiatric reviews with Professor Aziz , and/ or Senior nurse practitioner , and Dr Park: During this review neurosurgical parameters such as the degree of stimulation, and psychiatric parameters such as experience of eating disorder and comorbid psychiatric symptoms will be jointly assessed. Any necessary adjustments to stimulator intensity will then be programmed.

Post operative neuroimaging :

MEG resting state and food reward task based: (LO food preference task (OHBA, Warneford Hospital) - 30 minutes; at month 3 ( pre DBS switch on , 2 scans in month , 10 in DBS ON and OFF conditions , and end of study, month 15 Post operative Neuropsychological assessment 12 month after DBS on ie at 15 months. approximately 1 hour.

Optional post operative Ethics sub-study:

  • A separate, post operative ethics sub study will be optional and participants will be informed about this option in the main study patient information sheet, In the main study consent form they will be asked if they agree to being contacted about the ethics sub-study post operatively or not.
  • At the end of the study it will thus be possible to produce a detailed report of the ethics of the research, including the participant's perspective of the research experience

Optional Annual follow up phase for up to 5 years postop: repeating interview and questionnaires measures taken at entry and protocol end .

Being tested
DBS to nucleus accumbens/anterior limb of internal capsule
Keywords
Anorexia Nervosa, Treatment Development, Capacity, Neuroimaging, Magnetoencephalography, functional MRI, Reward processing, Habit formation
Medical subject headings
Anorexia Nervosa

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DBS to nucleus accumbens/anterior limb of internal capsuleDevice

    deep brain stimulation followed by 12 month post switch on followup

Study groups in NCT01924598
Study groupRoleWhat they receive
DBS surgeryExperimentalNot described
Receives: Device: DBS to nucleus accumbens/anterior limb of internal capsule

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse events associated with surgery or stimulation

    Measured: 13 months post operatively

  2. Eating Disorder pathology

    Global EDE Score, Yale brown ED scale

    Measured: 15 months

  3. Eating Disorder Pathology

    BMI

    Measured: 15 months

Secondary outcomes (4)
  1. Comorbid psychiatric symptoms

    anxiety, depression, obsessionality,

    Measured: 15 months

  2. Hamilton score

    hamilton depression rating scale

    Measured: 15 months

  3. MEG 'Resting State Network'

    Neural changes pre-post DBS

    Measured: 15 months

  4. Food Reward processing

    Leeds-Oxford food preference task: ' implicit 'wanting' of low vs hi cal foods, as indexed by reaction times to hi vs low cal food pictures.

    Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Aug 2013 (estimated)
  2. Study startJul 2013
  3. Primary completionJan 2025 (estimated)
  4. Study completionJun 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01924598
Sponsor's protocol ID
SC/13/0267
Status last verified
Mar 2020
First submitted
22 Jul 2013
Last updated
9 May 2024
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Park RJ, Scaife JC, Aziz TZ. Study Protocol: Using Deep-Brain Stimulation, Multimodal Neuroimaging and Neuroethics to Understand and Treat Severe Enduring Anorexia Nervosa. Front Psychiatry. 2018 Apr 6;9:24. doi: 10.3389/fpsyt.2018.00024. eCollection 2018.

    PubMed 29681866
  • Park RJ, Singh I, Pike AC, Tan JO. Deep Brain Stimulation in Anorexia Nervosa: Hope for the Hopeless or Exploitation of the Vulnerable? The Oxford Neuroethics Gold Standard Framework. Front Psychiatry. 2017 Mar 20;8:44. doi: 10.3389/fpsyt.2017.00044. eCollection 2017.

    PubMed 28373849

Questions about this trial

What is this clinical trial studying?

A study testing DBS to nucleus accumbens/anterior limb of internal capsule in people with Severe Enduring Anorexia Nervosa, run by University of Oxford at 2 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse events associated with surgery or stimulation (time frame: 13 months post operatively). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01924598, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in